Anti-PD-1, Capecitabine, and Oxaliplatin for the First-line Treatment of dMMR Positive Esophagogastric Cancer (AuspiCiOus-dMMR): a Proof-of-principle Study
Latest Information Update: 18 Sep 2022
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary) ; Retifanlimab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Pharmacodynamics; Proof of concept
- Acronyms AuspiCiOus
- 07 Jun 2022 Trial design presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 13 Aug 2021 New trial record